+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma

Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma

International Journal of Urology 21(7): 702-706

To investigate whether the combination of the imidazoquinoline immune response modifier, imiquimod, and the multitargeted tyrosine-kinase inhibitor, sorafenib, inhibits the growth of renal cell carcinoma in mice. Female BALB/c mice were implanted subcutaneously with 2 × 10(5) RENCA mouse kidney cancer cells, and were treated with transcutaneously applied cream containing imiquimod and oral administrations of sorafenib beginning 5 days after implantation of the cells. Tumor incidence and burden were determined at 28 days after initiation of therapy. T cell infiltration in the tumor was determined by immunofluorescence staining with anti-CD3-ε and CD8-α antibodies. Therapy with imiquimod, sorafenib or their combination was well tolerated. Combination therapy with imiquimod and sorafenib significantly inhibited tumor growth when compared with administration of control vehicle, imiquimod or sorafenib alone (P < 0.05). The CD3- and CD8-positive T cells infiltrated into tumors to a greater degree in response to the combination therapy when compared with tumors treated with control vehicle or sorafenib alone. Combination therapy with a tyrosine-kinase inhibitor and an imidazoquinoline could be a promising therapeutic strategy for patients with renal cell carcinoma.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054670213

Download citation: RISBibTeXText

PMID: 24571181

DOI: 10.1111/iju.12401

Related references

Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Oncology Letters 14(1): 1162-1166, 2017

Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clinical Genitourinary Cancer 4(3): 167-174, 2006

Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor. International Journal of Clinical Oncology 16(3): 275-278, 2011

Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clinical Genitourinary Cancer 5(4): 291-294, 2007

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. European Journal of Medical Research 15: 287-291, 2012

Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. Japanese Journal of Clinical Oncology 40(6): 503-507, 2010

First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11). Der Urologe. Ausg. a 53(5): 735-738, 2015

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Journal of Clinical Oncology 26(15_Suppl): 5127-5127, 2016

Combination therapy for perianal squamous cell carcinoma in situ with imiquimod and photodynamic therapy. Cutis 94(5): 252-254, 2015

Where does the combination of sorafenib and interferon in renal cell carcinoma stand?. Cancer 116(1): 4-7, 2010

Mp69-01 Nanotechnology Combination Therapy: Sorafenib Bound Gold Nanorods Produces Higher Treatment Response When Combined With Laser Thermal Ablation In A Renal Cell Carcinoma Animal Model. The Journal of Urology 193(4): e866-e867, 2015

Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology). Der Urologe. Ausg. a 50(10): 1319-1321, 2012

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. Annals of Oncology 26(9): 1871-1876, 2016

Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. Journal of Urology 190(1): 285-290, 2013

Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Value in Health Regional Issues 15: 120-126, 2018